Accordingly, EDN1 seems to be a potential therapeutic target of metastatic prostate cancer, and blocking the EDN1-EDNAR signaling pathway could potentially inhibit the progression of bone metastasis. The gene discussed is EDN1; the disease is bone metastasis.